D-Trp-Aib

D-Trp-Aib is a dipeptide and amyloid-β inhibitor with a K_d of 29.6 nM. D-Trp-Aib triggers formation of non-toxic, non-β-sheet, amorphous amyloid β clusters from misfolded amyloid β monomers and toxic amyloid β oligomers, and reduces toxic amyloid β_1-42 deposits. D-Trp-Aib inhibits amyloid fibril formation of α‑synuclein, IAPP and calcitonin. D-Trp-Aib can be used for the research of Alzheimer's disease^[1][2]. In Vitro:D-Trp-Aib (Compound 1) binds to Aβ_1-42 with an K_d of 29.6 ± 1.7 nM^[1].
D-Trp-Aib triggers the formation of larger, non-toxic amorphous and globular clusters from Aβ_1-42^[1].
D-Trp-Aib partially prevents Aβ_1-42-induced membrane potential depolarization^[1].
D-Trp-Aib (0.1 nM-1 μM; 90 min) reverses Aβ_1-42-induced LTP deficits in mouse hippocampal slices^[1].
D-Trp-Aib (molar ratio 1:10-1:30, 50 h) inhibits amyloid fibril formation of α‑synuclein, IAPP and calcitonin, and disassembles preformed amyloid fibrils^[2]. In Vivo:D-Trp-Aib (Compound 1) (0.5-2.0%; eye drops; three times daily; 3 months) produces a significant, dose-dependent reduction in toxic amyloid β_1-42 deposits in the retina of an AMD mouse model^[1].
D-Trp-Aib (0.5-2.0%; eye drops; three times daily; 1 month) reduces toxic amyloid β_1-42 deposits and associated complement component C3b inflammation in the retina of an aged AMD mouse model^[1].